Constitutive Expression of the ATP‐Binding Cassette Transporter ABCG2 Enhances the Growth Potential of Early Human Hematopoietic Progenitors

The ATP‐binding cassette transporter, ABCG2, is a molecular determinant of the side population phenotype, which is enriched for stem and progenitor cells in various nonhematopoietic and hematopoietic tissues. ABCG2 is highly expressed in hematopoietic progenitors and silenced in differentiated hematopoietic cells, suggesting a role of ABCG2 in early hematopoiesis. To test whether ABCG2 is involved in human hematopoietic development, we retrovirally transduced umbilical cord blood‐derived early hematopoietic cells and analyzed hematopoiesis in vitro and in vivo. ABCG2 increased the number of clonogenic progenitors in vitro, including the most primitive colony‐forming unit‐granulocyte, erythroid, macrophage, megakaryocyte, by twofold (n = 14; p < .0005). Furthermore, ABCG2 induced a threefold increase in the replating capacity of primary colonies (n = 9; p < .01). In addition, ABCG2 impaired the development of CD19+ lymphoid cells in vitro. In transplanted NOD/SCID mice, the ATP‐binding cassette transporter decreased the number of human B‐lymphoid cells, resulting in an inversion of the lymphoid/myeloid ratio. ABCG2 enhanced the proportion of CD34+ progenitor cells in vivo (n = 4; p < .05) and enhanced the most primitive human progenitor pool, as determined by limiting dilution competitive repopulating unit assay (p < .034). Our data characterize ABCG2 as a regulatory protein of early human hematopoietic development.

[1]  W. Zeller,et al.  No Evidence of Clonal Dominance in Primates up to 4 Years Following Transplantation of Multidrug Resistance 1 Retrovirally Transduced Long‐Term Repopulating Cells , 2007, Stem cells.

[2]  K. Parmar,et al.  Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia , 2007, Proceedings of the National Academy of Sciences.

[3]  P. Sonneveld,et al.  CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age , 2007, Annals of Hematology.

[4]  T. Holyoake,et al.  Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. , 2006, Blood.

[5]  M. Little,et al.  Kidney side population reveals multilineage potential and renal functional capacity but also cellular heterogeneity. , 2006, Journal of the American Society of Nephrology : JASN.

[6]  T. Takano-Yamamoto,et al.  The presence of ABCG2-dependent side population cells in human periodontal ligaments. , 2006, Biochemical and biophysical research communications.

[7]  J. Schuetz,et al.  Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.

[8]  R. Fanin,et al.  The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. , 2006, Haematologica.

[9]  H. Vankelecom,et al.  The adult pituitary contains a cell population displaying stem/progenitor cell and early embryonic characteristics. , 2005, Endocrinology.

[10]  R. Schneider-Broussard,et al.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. , 2005, Cancer research.

[11]  C. von Kalle,et al.  Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. , 2005, Blood.

[12]  P. Ney,et al.  Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. , 2005, Blood.

[13]  B. Uggla,et al.  BCRP mRNA expression v. clinical outcome in 40 adult AML patients. , 2005, Leukemia research.

[14]  J. Tisdale,et al.  Cloning and Functional Analysis of the Rhesus Macaque ABCG2 Gene: Forced Expression Confers an SP Phenotype among Hematopoietic Stem Cell Progeny in Vivo. , 2004 .

[15]  W. Greco,et al.  Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease‐free survival , 2004, British journal of haematology.

[16]  J. Schuetz,et al.  The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme* , 2004, Journal of Biological Chemistry.

[17]  J. Schuetz,et al.  Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Steinbach,et al.  BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia , 2002, Leukemia.

[19]  G. Sauvageau,et al.  Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. , 2002, Blood.

[20]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[21]  J. Meijerink,et al.  Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML) , 2002, Leukemia.

[22]  C. Chabannon,et al.  Forced expression of the Ikaros 6 isoform in human placental blood CD34(+) cells impairs their ability to differentiate toward the B-lymphoid lineage. , 2001, Blood.

[23]  A. Eaves,et al.  Transplantable hematopoietic stem cells in human fetal liver have a CD34(+) side population (SP)phenotype. , 2001, The Journal of clinical investigation.

[24]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[25]  D. Hogge,et al.  Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. , 2001, Blood.

[26]  C. Buske,et al.  Overexpression of HOXA10 perturbs human lymphomyelopoiesis in vitro and in vivo. , 2001, Blood.

[27]  J. Tisdale,et al.  The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. , 2001, Blood.

[28]  I. Weissman,et al.  Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. , 2001, Annual review of cell and developmental biology.

[29]  T. Lu,et al.  Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. , 2000, Blood.

[30]  M. Simon,et al.  Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. , 1999, Genes & development.

[31]  B. Sorrentino,et al.  Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. , 1998, Blood.

[32]  C. Eaves,et al.  Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Eaves,et al.  Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. , 1996, Blood.

[34]  A. S. Conner,et al.  Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo , 1996, The Journal of experimental medicine.

[35]  I. Pastan,et al.  Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. , 1991, Proceedings of the National Academy of Sciences of the United States of America.